Source comparison
MK-677 Clinical Trials 2026: Comparison of Study Designs and Endpoints
The following table compares the four major MK-677 clinical trials 2026 across key design parameters, allowing researchers to understand which trial addresses which clinical question and why endpoint selection differs based on population and hypothesis. | Tria
This comparison does not assign a generated winner or score.
- The following table compares the four major MK-677 clinical trials 2026 across key design parameters, allowing researchers to understand which trial addresses which clinical question and why endpoint selection differs based on population and hypothesis.
- | Trial Focus | Phase / Sites | Population | MK-677 Dose | Primary Endpoint | Duration | Bottom Line / Professional Assessment ||—|—|—|—|—|—|| Metabolic Syndrome & Sarcopenic Obesity | Phase III / 18 sites (US, Canada) | Adults 55–75, MetS + VAT >130 cm², low lean mass | 25mg daily | Visceral adipose tissue change (DEXA), fasting ISI, lean mass retention during deficit | 24 weeks | Largest and most metabolically complex cohort; first trial to use VAT as primary rather than secondary endpoint. Addresses whether MK-677 is viable for body recomposition in insulin-resistant populations || Mild Cognitive Impairment & Neurodegeneration | Phase II / 8 sites (EU) | Adults 60–80, MoCA 18–26, treatment-naive MCI | 12.5mg daily | Serum neurofilament light chain (NfL) change, BDNF, hippocampal volume (MRI) | 52 weeks | First cognitive trial using validated neurodegeneration biomarkers; longer duration allows detection of disease-modifying effects vs symptomatic; includes amyloid PET to rule out ac
- The comparison table demonstrates that MK-677 clinical trials 2026 are not attempting to answer the same question across different populations. Each trial targets a distinct clinical phenotype with endpoints mechanistically aligned to the hypothesis being tested. The metabolic syndrome trial uses visceral adipose tissue as the primary outcome because VAT is the depot most strongly associated with insulin resistance and cardiometabolic risk, and because ghrelin receptor expression in visceral adipocytes suggests a direct lipolytic effect independent of systemic GH. The cognitive trial measures neurofilament light chain because NfL is a fluid biomarker that reflects active neuronal injury, making it sensitive to disease-modifying interventions over 12-month timescales where cognitive testing alone might miss subtle changes. The borderline GH deficiency trial uses patient-reported outcomes alongside objective body composition because the clinical question is whether MK-677 can replicate t
- Anyone evaluating MK-677 for research applications in 2026 should cross-reference their population of interest and desired endpoints against these four trials. If studying metabolic outcomes, the Phase III MetS trial's design is the template. If investigating cognitive or neuroprotective applications, the MCI trial's biomarker panel (NfL, BDNF, MRI volumetrics, amyloid PET) represents the current standard for demonstrating CNS effects. For practical sourcing of research-grade MK-677 that meets the purity standards these institutional trials require, our MK 677 product line undergoes third-party verification with certificates of analysis provided per batch. Small-batch synthesis with exact sequencing ensures consistency across longitudinal studies where compound variability could confound results. Our experience supplying peptides to university and private research labs has shown that reagent quality is the variable investigators control least and regret most when results don't replicat